Peter Marks

106 papers receiving 5.3k citations

Peter Marks's Hit Papers

Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy 2024 · 164 citations
1640+3+6Years since publication4008001.2k

Peers

Peter Marks
Comparison fields: 5 of 165
  • Genetics 625
  • Hematology 622
  • Immunology and Allergy 318
  • Internal Medicine 152
  • Oncology 698
Replace Sylvia Heeneman with:
Sylvia Heeneman Netherlands
Elizabeth G. Nabel United States
Wouter W. van Solinge Netherlands
Eric R. Siegel United States
Anders Bjartell Sweden
Emile E. Voest Netherlands
Marion Kiechle Germany
Jan‐Willem J. Lammers Netherlands
Silvano Bòsari Italy
Fernando Augusto Soares Brazil
Peter Marks relative to Sylvia Heeneman Netherlands Sylvia Heeneman's profile →
Citations per field
00.5×3.5×
Sylvia Heeneman · 1×
Citations per year

Countries citing papers authored by Peter Marks

Since Specialization
Citations

This map shows the geographic impact of Peter Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Marks more than expected).

Fields of papers citing papers by Peter Marks

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Marks. The network helps show where Peter Marks may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Marks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Marks Line = papers co-authored together Peter Marks links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 115 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Real-World Evidence — What Is It and What Can It Tell Us?
Hit paper breakdown →
20161396
2 1999324
3 2003257
4 1990240
5 2006225
6 2016212
7
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Hit paper breakdown →
2021201
8 2000189
9
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
Hit paper breakdown →
2024164
10 2004124
11 2002124
12 2018121
13 2014105
14 1991101
15 199199
16 199087
17 200285
18 199875
19 199674
20 201367

About Peter Marks

Peter Marks is a scholar working on Molecular Biology, Hematology, Genetics, Infectious Diseases and Physiology, having authored 115 papers that have together received 5.5k indexed citations. Recurring topics across this work include Hemoglobinopathies and Related Disorders (14 papers), Venous Thromboembolism Diagnosis and Management (9 papers), Biomedical Ethics and Regulation (8 papers), Iron Metabolism and Disorders (8 papers), CAR-T cell therapy research (8 papers), SARS-CoV-2 and COVID-19 Research (7 papers), Blood donation and transfusion practices (6 papers) and Acute Myeloid Leukemia Research (6 papers). The work is most often cited by research in Genetics (625 citations), Hematology (622 citations), Immunology and Allergy (318 citations), Internal Medicine (152 citations) and Oncology (698 citations). Peter Marks has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Robert M. Califf, Frederick R. Maxfield, Janet Woodcock, Steven A. Anderson, Gerald J. Dal Pan, Gerry Gray, Danica Marinac‐Dabic, Jeffrey Shuren, Thomas P. Gross and Lilly Q. Yue. Their work appears in journals such as Blood, New England Journal of Medicine, Transfusion, JAMA and American Journal of Hematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact